
1. mol biochem parasitol. 2011 may;177(1):12-9. doi:
10.1016/j.molbiopara.2011.01.002. epub 2011 jan 18.

design anti-parasitic anti-fungal hydroxy-naphthoquinones less
susceptible drug resistance.

hughes lm(1), lanteri ca, o'neil mt, johnson jd, gribble gw, trumpower bl.

author information: 
(1)department biochemistry, dartmouth medical school, 7200 vail, hanover, nh
03755, usa.

atovaquone hydroxy-naphthoquinone used treat parasitic fungal
infections including plasmodium falciparum (malaria), pneumocystis jivorecii
(pneumonia) toxoplasma gondii (toxoplasmosis). blocks mitochondrial
oxidation ubiquinol organisms binding ubiquinol oxidation
site cytochrome bc(1) complex. failure atovaquone treatment been
linked appearance mutations mitochondrially encoded gene for
cytochrome b. order determine optimal parameters required for
inhibition respiration parasites pathogenic fungi overcome drug
resistance, synthesized tested inhibitory activity novel
hydroxy-naphthoquinones blood stage p. falciparum liver stage p.
berghei cytochrome bc(1) complexes isolated yeast strains
bearing mutations cytochrome b associated resistance plasmodium,
pneumocystis, toxoplasma. one new inhibitors highly effective
against atovaquone resistant plasmodium illustrates type of
modification hydroxy-naphthoquinone ring atovaquone might mitigate
drug resistance.

copyright Â© 2011 elsevier b.v. rights reserved.

doi: 10.1016/j.molbiopara.2011.01.002 
pmcid: pmc5054302
pmid: 21251932  [indexed medline]

